CN112313234B - 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物 - Google Patents

作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物 Download PDF

Info

Publication number
CN112313234B
CN112313234B CN201980024422.3A CN201980024422A CN112313234B CN 112313234 B CN112313234 B CN 112313234B CN 201980024422 A CN201980024422 A CN 201980024422A CN 112313234 B CN112313234 B CN 112313234B
Authority
CN
China
Prior art keywords
compound
alkyl
amino
pyrazolo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201980024422.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112313234A (zh
Inventor
张国良
周昌友
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN112313234A publication Critical patent/CN112313234A/zh
Application granted granted Critical
Publication of CN112313234B publication Critical patent/CN112313234B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980024422.3A 2018-04-08 2019-04-08 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物 Expired - Fee Related CN112313234B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/082140 2018-04-08
CN2018082140 2018-04-08
PCT/CN2019/081785 WO2019196803A1 (en) 2018-04-08 2019-04-08 Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist

Publications (2)

Publication Number Publication Date
CN112313234A CN112313234A (zh) 2021-02-02
CN112313234B true CN112313234B (zh) 2022-04-29

Family

ID=68163465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980024422.3A Expired - Fee Related CN112313234B (zh) 2018-04-08 2019-04-08 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物

Country Status (15)

Country Link
US (1) US11472811B2 (https=)
EP (1) EP3774813A4 (https=)
JP (1) JP2021520392A (https=)
KR (1) KR20200140849A (https=)
CN (1) CN112313234B (https=)
AU (1) AU2019251148A1 (https=)
BR (1) BR112020020078A2 (https=)
CA (1) CA3095839A1 (https=)
EA (1) EA202092036A1 (https=)
IL (1) IL277744A (https=)
MX (1) MX2020010618A (https=)
SG (1) SG11202009706VA (https=)
TW (1) TW202010500A (https=)
WO (1) WO2019196803A1 (https=)
ZA (1) ZA202005772B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010618A (es) 2018-04-08 2020-11-12 Beigene Ltd Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
CA3177057A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
WO2021191376A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
EP4214200A1 (en) 2020-10-22 2023-07-26 Nimmune Biopharma, Inc. Lancl ligands
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092264A1 (en) * 2000-05-26 2001-12-06 Schering Corporation Adenosine a2a receptor antagonists
WO2012038980A2 (en) * 2010-09-24 2012-03-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002347055B2 (en) 2001-10-08 2006-10-12 F. Hoffmann-La Roche Ag Substituted Triazolopyridine Compounds
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
MX2020010618A (es) 2018-04-08 2020-11-12 Beigene Ltd Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
CN110742893B (zh) 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092264A1 (en) * 2000-05-26 2001-12-06 Schering Corporation Adenosine a2a receptor antagonists
WO2012038980A2 (en) * 2010-09-24 2012-03-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist

Also Published As

Publication number Publication date
CN112313234A (zh) 2021-02-02
EP3774813A1 (en) 2021-02-17
TW202010500A (zh) 2020-03-16
US20210198267A1 (en) 2021-07-01
IL277744A (en) 2020-11-30
WO2019196803A1 (en) 2019-10-17
MX2020010618A (es) 2020-11-12
SG11202009706VA (en) 2020-10-29
ZA202005772B (en) 2022-01-26
CA3095839A1 (en) 2019-10-17
AU2019251148A1 (en) 2020-10-22
KR20200140849A (ko) 2020-12-16
BR112020020078A2 (pt) 2021-01-05
US11472811B2 (en) 2022-10-18
EP3774813A4 (en) 2021-11-17
JP2021520392A (ja) 2021-08-19
EA202092036A1 (ru) 2021-01-28

Similar Documents

Publication Publication Date Title
US12454534B2 (en) Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof
CN112313234B (zh) 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物
CN114341127B (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN115335376A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶（btk）及其使用方法
KR20210125026A (ko) Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
CN115003667A (zh) Tyk-2抑制剂
CN110267959B (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
WO2018045971A1 (zh) 吡啶并五元芳香环类化合物、其制备方法及用途
CN110742893B (zh) A2a受体拮抗剂治疗癌症的方法
HK40036174A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
TW202024072A (zh) 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物
HK40074764A (en) Tyk-2 inhibitor
WO2024153233A1 (en) Compounds and their uses as gpr17 antagonists
HK40073633A (en) Pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
WO2024230803A1 (en) Isoquinolinone derivatives and 4h-quinolizinone derivatives and pharmarceutical compositions thereof for the treatment of disease
HK40076737A (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
HK40061243A (en) Pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
HK40098888A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
HK40098888B (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
HK40085463A (en) Tyk-2 inhibitor
TW202409028A (zh) Lrrk2抑制劑
HK40098887A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
HK40040196A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036174

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220429

CF01 Termination of patent right due to non-payment of annual fee